2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 343-345
Technology and Procedures, Omics Technologies, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Biological Processes, Immune Mechanism, Metabolism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human
PAPER

277 Engineered CART cells secreting anti-CSF1R molecules deplete suppressive myeloid cells and enhance tumor control without systemic toxicity

Grace Elizabeth DeFranco, BS, Jennifer Meyer Feigin, BS2, Brooke L Kimball3, Elizabeth Louise Siegler, PhD4, Claudia Manriquez-Roman, PhD5, Long K Mai, BS6, Truc Ngoc Huynh, MS7, Omar Gutierrez-Ruiz, PhD8, Ismail Can, PhD9, Yoh Yamaguchi, MD10, Sophia Yael Goldberg11, Dominic Ambrosio Skeele12, Ateka Saleh13, Charles Joseph Kuhlmann, PhD14, Mehrdad Hefazi Torghabeh, MD15, Ying Li, PhD16, Yi Lin Jr, MD, PhD17, John Al Copland III, PhD18, R. Leo Sakemura, MD,PhD19, Saad Kenderian, M.B., Ch.B.20
1 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Jacksonville, Florida, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Jacksonville, Florida, United States, Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States

Chimeric antigen receptor T (CART) cell therapy has shown unprecedented success in hematological malignancies, but its efficacy is limited by the tumor microenvironment (TME). Tumor-associated myeloid cells suppress CART function, whereas inflammatory myeloid cells enhance antitumor immunity. We investigated CART–myeloid cell interactions and developed a strategy to target suppressive myeloid cells within the TME without systemic depletion. In the study, we utilized preclinical lymphoma models, and samples from patients treated with CART19, and validated our findings in preclinical thyroid cancer models.

To study the impact of suppressive myeloid cells, human CART19 (FMC63-41BBζ) or TSHR-CART (K170-41BBζ) cells were co-cultured with  CD19+ JEKO-1 or  TSHR+ 8505C cells, respectively in the presence of M2 like macrophages. CART antigen specific proliferation was significantly inhibited by M2 like macrophages compared with non-polarized macrophages (p=0.003, p=0.004, respectively). In an immunocompetent model of lymphoma, TBL-12 cells were engrafted i.v. in C57BL/6 mice to a high disease burden and treated with suboptimal doses of murine CART19 (αmCD19-28ζ). In these mice, an increased number of suppressive myeloid cells (CD206high) in lymph nodes correlated with higher tumor burden (R2=0.699). Unexpectedly, systemic myeloid cell depletion with clodronate in this model impaired CART efficacy, resulting in significantly greater tumor burden than CART alone (tumor flux: 1x1010 vs 3x108, p<0.0001).

We therefore pursued selective targeting of tumor-associated myeloid cells through targeting colony-stimulating factor 1 receptor (CSF1R), a regulator of myeloid cell survival. CSF1R was significantly upregulated on M2-polarized macrophages in vitro (p=0.003). In a TBP-3743 immunocompetent model of thyroid cancer in C57BL/6 mice, CSF1R expression in the tumor and spleen significantly correlated with increased tumor size (R2=0.689, R2=0.798). In 32 patients with relapsed large B-cell lymphoma treated with axi-cel, higher CSF1R expression on CD14+ and CD16+ myeloid cells one month after therapy was strongly associated with progressive disease versus complete response (adjusted p=2.719×10?4² and 1.162×10?¹6³).

To locally target CSF1R, we engineered CART cells to secrete a tri-specific anti-CD16, IL-15, anti-CSF1R VHH engager (STriKE), to recruit NK cells and eliminate CSF1R+ myeloid cells. STriKE secretion increased following CART19 activation (6 vs 3 pg/ml, p<0.0001). Flow cytometry confirmed STriKE binding to CSF1R+ macrophages and CD16+ NK cells (38%, p=0.004; 35%, p=0.0003). STriKEs significantly enhanced NK killing of CSF1R+ THP-1 myeloid cells (p<0.0001).

In lymphoma preclinical models, NOD/SCID/IL2Rg null (NSG) mice bearing luciferase+ JEKO-1 cells (1x106 i.v.), engrafted with donor matched PBMCs (1x107 cells i.v.), and treated with STriKE-CART19 (1x106 i.v.) demonstrated superior tumor control compared to conventional CART19 or CART19 secreting IL-15 (tumor flux: 9x107 vs 9x108 vs 6x108 p/s, both p<0.0001) and improved CART expansion (p=0.0105, p=0.0282). In the immunocompetent TBL-12 lymphoma model, murine STriKE-CART19 induced rapid tumor clearance versus CART19 alone or CART19 plus anti-CSF1R antibody (tumor flux: 5x106 vs 1x1010 vs 3x1010 p/s, p=0.005, and p<0.0001), significantly prolonged overall survival (100% survival to day 50 vs median survival 15 days, p<0.0001), and increased circulating CART cells (p=0.0014, p=0.0006). Importantly, resident alveolar macrophages and Kupffer cells were preserved following STriKE-CART19, supporting selective targeting of tumor-associated myeloid cells.

In anaplastic thyroid cancer models, STriKE-TSHR-CART significantly enhanced CART cytotoxicity in both 2D and 3D coculture models containing 8505C, CART, macrophages, and NK cells (p=0.0089, p=0.0387). In NSG mice bearing established 8505C tumors (implanted subQ, established tumor ~100m3), STriKE-TSHR-CART (1x106 i.v.) achieved superior tumor control compared with TSHR-CART plus anti-CSF1R antibody (p=0.0110) and significantly increased circulating CART cell peripheral blood proliferation (p=0.0035).

Together, our results highlight CSF1R targeting through STriKE-CART as an effective strategy to safely overcome myeloid cell suppression without impairing CART activity. Compared with anti-CSF1R antibody therapy, STriKE-CART produced superior tumor control, CART expansion, and survival across multiple preclinical models with suppressive TMEs.

Grace Elizabeth DeFranco, BS: No relevant conflicts of interest to declare.